Log in
NASDAQ:NVCR

Novocure Stock Forecast, Price & News

$122.10
-1.17 (-0.95 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$120.02
Now: $122.10
$125.50
50-Day Range
$87.40
MA: $117.07
$138.72
52-Week Range
$53.40
Now: $122.10
$140.89
Volume977,842 shs
Average Volume1.00 million shs
Market Capitalization$12.34 billion
P/E Ratio1,017.58
Dividend YieldN/A
Beta1.41
Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Read More
Novocure logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.53 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVCR
CUSIPN/A
Phone44-0-15-3475-6700
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$351.32 million
Book Value$2.20 per share

Profitability

Net Income$-7,230,000.00

Miscellaneous

Market Cap$12.34 billion
Next Earnings Date2/25/2021 (Estimated)
OptionableOptionable
$122.10
-1.17 (-0.95 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVCR News and Ratings via Email

Sign-up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Novocure (NASDAQ:NVCR) Frequently Asked Questions

How has Novocure's stock been impacted by Coronavirus (COVID-19)?

Novocure's stock was trading at $67.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVCR shares have increased by 81.2% and is now trading at $122.10.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Novocure?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Novocure
.

When is Novocure's next earnings date?

Novocure is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Novocure
.

How were Novocure's earnings last quarter?

Novocure Ltd (NASDAQ:NVCR) announced its earnings results on Thursday, October, 29th. The medical equipment provider reported $0.09 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.04 by $0.05. The medical equipment provider earned $132.70 million during the quarter, compared to analyst estimates of $120.02 million. Novocure had a return on equity of 5.14% and a net margin of 2.88%. The firm's revenue was up 44.1% on a year-over-year basis. During the same period last year, the business posted $0.02 earnings per share.
View Novocure's earnings history
.

What price target have analysts set for NVCR?

10 Wall Street analysts have issued 12 month target prices for Novocure's shares. Their forecasts range from $58.00 to $150.00. On average, they anticipate Novocure's share price to reach $99.67 in the next year. This suggests that the stock has a possible downside of 18.4%.
View analysts' price targets for Novocure
.

Are investors shorting Novocure?

Novocure saw a increase in short interest in September. As of September 30th, there was short interest totaling 5,330,000 shares, an increase of 41.4% from the September 15th total of 3,770,000 shares. Based on an average daily trading volume, of 961,000 shares, the days-to-cover ratio is currently 5.5 days. Currently, 6.4% of the company's shares are short sold.
View Novocure's Short Interest
.

Who are some of Novocure's key competitors?

What other stocks do shareholders of Novocure own?

Who are Novocure's key executives?

Novocure's management team includes the following people:
  • Asaf Danziger, Chief Executive Officer & Director
  • Mike Ambrogi, Chief Operating Officer
  • Wilco Groenhuysen, CFO & Chief Accounting Officer
  • Eilon D. Kirson, Chief Science Officer, Head-Research & Development
  • Uri Weinberg, Vice President-Clinical Development

What is Novocure's stock symbol?

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

Who are Novocure's major shareholders?

Novocure's stock is owned by a variety of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.41%), Kornitzer Capital Management Inc. KS (0.17%), Peregrine Capital Management LLC (0.13%), Scout Investments Inc. (0.10%), State of New Jersey Common Pension Fund D (0.06%) and Taylor Frigon Capital Management LLC (0.05%). Company insiders that own Novocure stock include Asaf Danziger, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends for Novocure
.

Which institutional investors are selling Novocure stock?

NVCR stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, BNP Paribas Arbitrage SA, State of New Jersey Common Pension Fund D, CWM LLC, Envestnet Asset Management Inc., Kornitzer Capital Management Inc. KS, Amalgamated Bank, and IFP Advisors Inc. Company insiders that have sold Novocure company stock in the last year include Asaf Danziger, Charles G Phillips III, Ely Benaim, Gabriel Leung, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen, and William F Doyle.
View insider buying and selling activity for Novocure
.

Which institutional investors are buying Novocure stock?

NVCR stock was acquired by a variety of institutional investors in the last quarter, including Scout Investments Inc., Hodges Capital Management Inc., Rhenman & Partners Asset Management AB, Eagle Global Advisors LLC, Standard Life Aberdeen plc, Exchange Traded Concepts LLC, IBM Retirement Fund, and NewFocus Financial Group LLC.
View insider buying and selling activity for Novocure
.

How do I buy shares of Novocure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novocure's stock price today?

One share of NVCR stock can currently be purchased for approximately $122.10.

How big of a company is Novocure?

Novocure has a market capitalization of $12.34 billion and generates $351.32 million in revenue each year. The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.

What is Novocure's official website?

The official website for Novocure is www.novocure.com.

How can I contact Novocure?

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.